%0 Journal Article
%T Feasibility Study for Biweekly  Administration of Cisplatin plus Vinorelbine as Adjuvant-Chemotherapy for Completely Resected Non-Small Cell Lung Cancer  Patients in a Japanese Population
%A Shuichi Tsukamoto
%A Koji Yamazaki
%A Ryo Mori
%A Masakazu Katsura
%A Hidenori Kouso
%A Daigo Kawano
%A Chie Ushijima
%A Sadanori Takeo
%J Advances in Lung Cancer
%P 1-9
%@ 2169-2726
%D 2014
%I Scientific Research Publishing
%R 10.4236/alc.2014.31001
%X <p style=\"text-align:justify;\">
	<span \"=\"\" style=\"line-height:1.5;font-family:Verdana;\">Purpose: To evaluate the feasibility of
biweekly administration of cisplatin and vinorelbine as adjuvant chemotherapy
for patients with completely resected non-small cell lung cancer (NSCLC). Patients
and Methods: This was a single-arm, single-institutional study. Patients with
completely resected NSCLC (p-Stage IB-IIIA) with no previous chemotherapy or
radiotherapy were eligible. Simon</span><span \"=\"\" style=\"line-height:1.5;font-family:Verdana;\">กฏ</span><span \"=\"\"><span style=\"font-family:Verdana;\">s optimal two-stage design was applied. Both
cisplatin (50 mg/m</span><sup><span style=\"font-family:Verdana;\">2</span></sup><span style=\"font-family:Verdana;\">) and vinorelbine (25 mg/m</span><sup><span style=\"font-family:Verdana;\">2</span></sup><span style=\"font-family:Verdana;\">) were
given on days 1 and 15, every 28 days. The primary endpoint of this study was
the feasibility of this combination in the four cycles of treatment. Results:</span></span><span \"=\"\"> </span><span \"=\"\"><span style=\"font-family:Verdana;\">Twenty patients (19 lobectomies and 1
pneumonectomy) were enrolled in this study. 10</span><i> </i><span style=\"font-family:Verdana;\">(50%) of patients had
grade 3/4 neutropenia, and 3 (15%) had grade 3/4 anemia. Severe non-hematologic
toxicities were uncommon in this series. No treatment-related death was
encountered. 18 (90%) patients completed the planned 4 cycles of chemotherapy.
The median intensity was 24.3 (range 18.1 to 25) mg/m</span><sup><span style=\"font-family:Verdana;\">2</span></sup><span style=\"font-family:Verdana;\">/week with an
average of 23.6 (21</span></span><span \"=\"\"> </span><span \"=\"\" style=\"line-height:1.5;font-family:Verdana;\">-</span><span \"=\"\"> </span><span \"=\"\"><span style=\"font-family:Verdana;\">25) mg/m</span><sup><span style=\"font-family:Verdana;\">2</span></sup><span style=\"font-family:Verdana;\">/week cisplatin and 12.5
(range</span></span><span \"=\"\"> </span><span \"=\"\"><span style=\"font-family:Verdana;\">10 to 12.5) mg/m</span><sup><span style=\"font-family:Verdana;\">2</span></sup><span style=\"font-family:Verdana;\">/week
with an average of 12.3 (10</span></span><span \"=\"\"> </span><span \"=\"\" style=\"line-height:1.5;font-family:Verdana;\">-</span><span \"=\"\"> </span><span \"=\"\"><span style=\"font-family:Verdana;\">12.5) mg/m</span><sup><span style=\"font-family:Verdana;\">2</span></sup><span style=\"font-family:Verdana;\">/week vinorelbine. The
median
%K NSCLC
%K Adjuvant Chemotherapy
%K Cisplatin and Vinorelbine
%K Biweekly
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=42970